

Statin Drug Interactions

Drug	Action	Comment
Atorvastatin		
PIs atazanavir darunavir/rtv fosamprenavir indinavir lopinavir/rtv nelfinavir saquinavir/rtv tipranavir/rtv ritonavir	Start with 10mg dose Start with 10mg dose Start with 10mg dose Start with 10mg dose Start with 10mg dose Start with 10mg dose Start with 10mg dose Avoid combination Start with 10mg dose	No data with atazanavir alone AUC increases 400% AUC increased 130% No data AUC increased 488% AUC increased 74% AUC increased 79% AUC increased 10-fold; use 10mg if necessary Start with lowest dose for all RTV boosted regimens
NNRTIs efavirenz nevirapine etravirine	Standard dose Standard dose Standard dose	AUC decreased 43%; monitor cholesterol and increase atorvastatin dose to effect No data, monitor cholesterol and adjust atorvastatin dose to effect AUC decreased 37%, monitor cholesterol and increase atorvastatin dose to effect
Integrase raltegravir	Standard dose	Raltegravir is not expected to affect drugs that are substrates of UDP-glucuronosyltransferases
CCR5 maraviroc	Standard dose	Coadministration not studied, but no interaction is expected
Pravastatin		
PIs atazanavir darunavir/rtv fosamprenavir indinavir lopinavir/rtv nelfinavir saquinavir/rtv tipranavir/rtv ritonavir	Standard dose Avoid combination Standard dose Standard dose Standard dose Standard dose Standard dose Standard dose Standard dose	No data; interaction not expected AUC increased 81% with large variability No data; interaction not expected No data; interaction not expected AUC increased 33% AUC decreased 47%; increase dose to effect AUC decreased 50%; increase dose to effect No data available. Potentially RTV boosted regimens AUC decreased 50%; increase dose to effect
NNRTIs efavirenz nevirapine etravirine	Standard dose Standard dose Standard dose	AUC decreased 44%; monitor cholesterol and increase pravastatin dose to effect No data, interaction unlikely No data, although interaction unlikely, monitor cholesterol and adjust pravastatin dose to effect
Integrase raltegravir	Standard dose	Raltegravir is not expected to affect drugs that are substrates of UDP-glucuronosyltransferases
CCR5 maraviroc	Standard dose	Coadministration not studied, but no interaction is expected

Simvastatin		
PIs All	Avoid all combinations	Large increases in simvastatin concentrations – Simvastatin is contraindicated w/ all PIs
NNRTIs efavirenz nevirapine etravirine	Standard dose Standard dose Standard dose	AUC decreased 66%; monitor cholesterol and increase simvastatin dose to effect Monitor cholesterol and adjust simvastatin dose to effect; may result in lower levels of simvastatin No data, co-administration may result in lower plasma levels of simvastatin, monitor cholesterol and adjust simvastatin dose to effect
Integrase raltegravir	Standard dose	Raltegravir is not expected to affect drugs that are substrates of UDP-glucuronosyltransferases
CCR5 maraviroc	Standard dose	Coadministration not studied, but no interaction is expected
<u>Rosuvastatin*</u>		
PIs atazanavir darunavir/rtv fosamprenavir indinavir lopinavir/rtv nelfinavir saquinavir/rtv tipranavir/rtv ritonavir boosted	Max dose 10mg/day Standard Dose Standard Dose Standard Dose Max dose 10mg/day Standard Dose Standard Dose Standard Dose Start with 5mg dose See boosted agent	200% increase in AUC, 600% increase in Cmax w/ RTV boosted ATV. Titrated with caution No clinical data. Potential for increase in plasma levels. AUC increased 8%, Cmax increased by 45% Increased AUC possible (non-boosted IDV) 2.1 fold increase in AUC, 4.7 fold increase in Cmax; Titrated with caution No clinical data No clinical data AUC increased 26%, 2-fold increase in Cmax; Titrated with caution Start with lowest effective dose for all RTV boosted regimens
NNRTIs efavirenz nevirapine etravirine	Standard dose Standard dose Standard dose	Interaction unlikely, monitor cholesterol Interaction unlikely, monitor cholesterol Interaction unlikely, monitor cholesterol
Integrase raltegravir	Standard dose	Raltegravir is not expected to affect drugs that are substrates of UDP-glucuronosyltransferases
CCR5 maraviroc	Standard dose	Coadministration not studied, but no interaction is expected
Lovastatin		
PIs All	Avoid all combinations	Potential increases in lovastatin concentrations
NNRTIs EFV Etravirine/NVP	No data	No data Decreased lovastatin is possible; monitor cholesterol and adjust lovastatin to effect
Integrase raltegravir	Standard dose	Raltegravir is not expected to affect drugs that are substrates of UDP-glucuronosyltransferases or PGP
CCR5 maraviroc	Standard dose	Coadministration not studied, but no interaction is expected